Jane E Schrimpf

Title: Innovations by Jane E. Schrimpf in Antiviral Vaccines

Introduction

Jane E. Schrimpf is an accomplished inventor based in St. Louis, MO. She has made significant contributions to the field of immunology, particularly in the development of antiviral vaccines. Her innovative work focuses on enhancing immune responses to specific viruses, showcasing her dedication to advancing medical science.

Latest Patents

Jane E. Schrimpf holds a patent for a groundbreaking invention titled "Virus-expressing host costimulation molecules." This antiviral vaccine encodes costimulation molecules that are crucial for increasing the immune response to targeted viruses. In her research, she demonstrated the importance of these molecules in generating immunity against herpes simplex virus (HSV) infections, particularly in mice lacking both B7-1 and B7-2. The findings indicate that the expression of B7-1 or B7-2 by replication-defective HSV can enhance its immunogenicity and protective capacity.

Career Highlights

Jane is affiliated with Saint Louis University, where she continues her research and development efforts. Her work has been instrumental in understanding the mechanisms of viral infections and the immune responses they elicit. With her innovative approach, she has contributed to the advancement of antiviral therapies.

Collaborations

Jane has collaborated with notable colleagues, including Lynda Anne Morrison and Lydia G. Thebeau. These partnerships have enriched her research and expanded the impact of her work in the field of immunology.

Conclusion

Jane E. Schrimpf's contributions to antiviral vaccine development highlight her role as a leading inventor in the field. Her innovative research continues to pave the way for advancements in immunology and public health.